^
    Back
    Association details:
    Biomarker:NF2 K159fs*16
    Cancer:Breast Cancer
    Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Ann Oncol
    Title:

    Inhibition of the phosphoinositide 3-kinase pathway for the treatment of patients with metastatic metaplastic breast cancer

    Excerpt:
    Patients with mesenchymal/MpBC treated with temsirolimus-based regimens were evaluated...A point mutation in the NF2 gene (K159fs*16; NF2 alterations can activate mTor) was found in one patient who attained CR (3+ years).
    Secondary therapy:
    temsirolimus + pegylated liposomal doxorubicin
    DOI:
    10.1093/annonc/mdv163